Clinical update and financing reshape Monte Rosa Therapeutics (GLUE) story Monte Rosa Therapeutics (GLUE) is back in focus after updated Phase 1/2 data for MRT-2359 in metastatic castration-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results